Literature DB >> 3382169

Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.

G M McKhann1, J W Griffin, D R Cornblath, E D Mellits, R S Fisher, S A Quaskey.   

Abstract

The time course of recovery in the Guillain-Barré syndrome is known to vary widely, but factors associated with differences have not been previously defined. In this study we used multivariate analysis to identify such factors and to determine whether the presence or absence of specific factors would influence treatment decisions, particularly the use of plasmapheresis. Data from 245 patients randomized into conventional and plasmapheresis arms were used to assess the time to walk independently (Grade 2), the time to improve one grade, and the percentage improved at 4 weeks. Individually, many factors were associated with outcome. In the multivariate analysis, four factors correlate with poorer outcomes: mean amplitude of compound muscle action potential on stimulating distally of 20% of normal or less, older age, time from onset of disease of 7 days or less, and need for ventilatory support. The most powerful predictor of outcome was the abnormal mean amplitude of compound muscle action potential on stimulating distally. Plasmapheresis, the only variable the physician can influence, has a beneficial effect over and above any or all of these factors. The plasmapheresis patients on continuous flow machines had better outcomes than those on intermittent flow machines. From these data, tables of expected outcome probabilities have been developed.

Entities:  

Mesh:

Year:  1988        PMID: 3382169     DOI: 10.1002/ana.410230406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients.

Authors:  R K Lyu; L M Tang; S Y Cheng; W C Hsu; S T Chen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

2.  Influence of plasma exchange pheresis on plasma elimination of ceftriaxone.

Authors:  J S Bakken; S J Cavalieri; D Gangeness
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Peripheral neuropathy: clinical and electrophysiological considerations.

Authors:  Tae Chung; Kalpana Prasad; Thomas E Lloyd
Journal:  Neuroimaging Clin N Am       Date:  2013-05-25       Impact factor: 2.264

4.  Guillain-Barré syndrome in pregnancy--two case reports and a discussion on management.

Authors:  A Bolik; J Wissel; A Rolfs
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

5.  Epidemiology of peripheral neuropathy.

Authors:  C N Martyn; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

6.  Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.

Authors:  A Hiraga; M Mori; K Ogawara; S Kojima; T Kanesaka; S Misawa; T Hattori; S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

7.  Residual health status after Guillain-Barré syndrome.

Authors:  R A Bernsen; H M Jacobs; A E de Jager; F G van der Meché
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

8.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

Review 9.  Respiratory aspects of neurological disease.

Authors:  M I Polkey; R A Lyall; J Moxham; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

10.  An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.